SCHEMBL3495891

SCHEMBL3495891

COc1ccc(-n2ncc(C(=O)O)c2-c2ccccc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.61
NFE2L2 Q16236 1/20 0.61
MAPK14 Q16539 1/20 0.58
ALDH1A1 P00352 4/20 0.57
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
MAPT P10636 2/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
RPA1 P27694 1/20 0.54
HTT P42858 2/20 0.54
LMNA P02545 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
PTPN1 P18031 1/20 0.54
HIF1A Q16665 1/20 0.53
PKM P14618 1/20 0.53
KDM4E B2RXH2 2/20 0.52
GAA P10253 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3493556 0.87 KEAP1 (0.64) KEAP1NFE2L2ALDH1A1NPC1RAB9A
SCHEMBL4497271 0.85 ALDH1A1 (0.65) KEAP1NFE2L2MAPK14ALDH1A1NPC1
SCHEMBL23398941 0.82 HTT (0.54) MAPK14ALDH1A1NPC1RAB9AMAPT
SCHEMBL2855932 0.80 NPC1 (0.69) MAPK14ALDH1A1NPC1RAB9AMAPT
SCHEMBL31276354 0.79 NPBWR1 (0.56) MAPK14ALDH1A1NPC1RAB9AMAPT
SCHEMBL3296237 0.79 PTPN1 (0.79) MAPK14ALDH1A1NPC1RAB9AMAPT
SCHEMBL10365375 0.79 PTPN1 (0.57) MAPK14ALDH1A1NPC1RAB9AMAPT
SCHEMBL3493407 0.78 MAPK14 (0.58) KEAP1NFE2L2MAPK14ALDH1A1HTT
SCHEMBL4333963 0.77 KDM4E (0.58) KEAP1NFE2L2ALDH1A1NPC1RAB9A
SCHEMBL21409674 0.77 MAPK14 (0.57) KEAP1NFE2L2MAPK14ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140178503-A1 CYCLOHEXYL UREA MODULATORS OF D2 RECEPTORS AND/OR D3 RECEPTORS AUSPEX PHARMACEUTICALS, INC. (US) 2014-06-26 US disclosed
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
EP-1984355-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION Takeda Pharmaceutical Company Limited (JP) 2008-10-29 EP disclosed
WO-2007094513-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 KEAP1 488/4885NFE2L2 1103/4885MAPK14 1316/4885
US-20140178503-A1 CYCLOHEXYL UREA MODULATORS OF D2 RECEPTORS AND/OR D3 RECEPTORS UTS2R, VDR, PTGDR KEAP1 3327/4885NFE2L2 2117/4885MAPK14 3796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.